title: Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences.
abstract: Over the last 12 years, the pharmacological management of glaucoma and ocular hypertension has significantly changed with the introduction of the prostaglandin analogs, specifically, latanoprost, bimatoprost, and travoprost. Their ability to effectively reduce intraocular pressure with once-per-day dosing, their comparable ocular tolerability with timolol, and their general lack of systemic side effects have made them the mainstay of pharmacological therapy for glaucoma and ocular hypertension in most parts of the world. A review of their pharmacology reveals that they are all prodrugs that are converted to their respective free acids within the eye to activate the prostanoid FP receptor and to reduce intraocular pressure by enhancing the uveoscleral and the trabecular meshwork outflow pathways. A review of numerous prospective, randomized comparative studies indicates that no clinically significant differences exist among these agents regarding their ability to lower intraocular pressure.
authors.affiliation: Burkett, Texas, USA.
authors.forename: Gerald W
authors.initials: GW
authors.lastname: Bean
authors.forename: Carl B
authors.initials: CB
authors.lastname: Camras
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D009798:Ocular Hypertension / Q000188:drug therapy; D011355:Prodrugs / Q000627:therapeutic use*; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D011355:Prodrugs; D011461:Prostaglandins F, Synthetic